€345.7 Million
EUR as of July 1, 2024
US$371.3 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic medicine and plastic surgery in Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, and Australia. The company operates in two segments, Beauty and Trade. It develops and markets pharmaceutical, medical, and medical technology products for aesthetic medicine, plastic surgery, and cosmetic dermatology, as well as trades in pharmaceutical, biosimilars, and other medical products in the areas of oncology, HIV, rheumatism, neurology, cardiovascular diseases, and narcotics. The company also engages in the acquisition, development, operation, and sale of real estate, primarily in the health care sector. In addition, it offers its products to private customers, doctors, pharmacies, and wholesalers under the M1 Select brand. It operates a network of outpatient specialist centers for beauty treatments; and a specialist surgical clinic centre, as well as 38 specialist centres under the M1 Med Beauty brand. M1 Kliniken AG was founded in 2007 and is based in Berlin, Germany. M1 Kliniken AG is a subsidiary of MPH Health Care AG.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
M1 Kliniken AG has the following listings and related stock indices.
Stock: FSX: M12 wb_incandescent
Stock: XETR: M12 wb_incandescent